Skip to main content
. 2020 May 26;21(7):829–837. doi: 10.3348/kjr.2019.0672

Table 2. Univariate and Multivariate Analyses for 3-Year Post-Recurrence Survival.

Variables Univariate Analysis Multivariate Analysis
HR (95% CI) P HR (95% CI) P
Age at diagnosis, years
 < 50*
 ≥ 50 1.57 (0.80–3.06) 0.187
Sex
 Male*
 Female 0.54 (0.27–1.09) 0.086
Type of gastrectomy
 Total*
 Subtotal 0.69 (0.35–1.36) 0.282
Pathologic T stage
 T1*
 T2 1.35 (0.32–5.71) 0.682
 T3 0.86 (0.21–3.61) 0.837
 T4 1.77 (0.53–5.89) 0.355
Pathologic N stage
 N0*
 N1 0.78 (0.17–3.69) 0.754
 N2 2.39 (0.79–7.13) 0.119
 N3 2.01 (0.89–4.51) 0.091
TNM stage
 I*
 II 0.95 (0.26–3.53) 0.942
 III 1.79 (0.54–5.97) 0.337
Histopathologic subtype
 Adenocarcinoma*
 Signet ring cell 1.26 (0.65–2.43) 0.493
Lauren histotype
 Diffuse*
 Intestinal 0.68 (0.33–1.41) 0.298
LNR
 ≤ 0.063*
 > 0.063 2.22 (1.12–4.43) 0.023
SUVmax
 ≤ 5.1*
 > 5.1 3.30 (1.58–6.87) 0.001 2.57 (1.16–5.69) 0.012
Weight loss, %
 ≤ 14.7*
 > 14.7 2.91 (1.48–5.71) 0.002 2.24 (1.11–4.56) 0.025
Hemoglobin, g/dL
 ≥ 11.4*
 < 11.4 1.88 (0.98–3.58) 0.055
Neutrophil count, cells/uL
 ≤ 2997*
 > 2997 2.89 (1.45–5.79) 0.003 2.68 (1.32–5.43) 0.006
Lymphocyte count, cells/uL
 ≤ 1084*
 > 1084 0.58 (0.30–1.10) 0.095
Platelet count, cells/uL
 ≥ 154000*
 < 154000 2.16 (0.88–5.31) 0.094
Recurrence timing
 Early, ≤ 2 years 2.40 (1.18–4.91) 0.016
 Late, > 2 years*
First sites of recurrence
 Locoregional recurrence only*
 Distant metastasis only 1.49 (0.52–4.31) 0.458
 Locoregional and distant failure 2.62 (0.81–8.41) 0.107

*Reference of categorical parameter, According to 8th AJCC staging system. CI = confidence interval, HR = hazard ratio